The acquisition will expand and strengthen Veranex’s regulatory affairs, clinical development and quality assurance services for medtech companies, including an improved ability to navigate EU-MDR/IVDR challenges thanks to Medidee’s experience in the European regulatory space.
“Our acquisition of Medidee significantly expands our European footprint while also materially expanding the scale and scope of the clinical studies we can manage,” said David Dockhorn, CEO of Veranex. “The combined organization offers offices and expertise across Europe, the U.S. and Asia, augmenting our ability to help MedTech innovators achieve FDA and CE Mark approvals and uninterrupted market access for new as well as proven medical technologies that advance patient care.”
Medidee has 11 locations across Europe, India and Asia-Pacific. Veranex has 13 locations across the U.S., Europe and China. The combined companies will offer a full spectrum of integrated concept-to-commercialization services, including design, engineering, regulatory, quality, preclinical research, clinical development, clinical operations, commercial strategy and market access services.